ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

Slides:

Advertisements

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Advertisements

Presented by Bo Olsson (AstraZeneca)

Participation Requirements for a Guideline Panel Member.

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Parametric Tolerance Interval (PTI) Test for Delivered Dose Uniformity (DDU) for Orally Inhaled and Nasal Drug Products (OINDP) Michael Golden On behalf.

Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables PQRI Leachables & Extractables Working Group PQRI Training Course.

Logo Next Welcome to an interactive overview of the Non-GMO Project. Throughout the presentation, please click on any underlined links to be connected.

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

ITFG/IPAC Collaboration Conclusion ITFG/IPAC COLLABORATION: CONCLUDING REMARKS Presented by: Cynthia Flynn, PhD 26 April 2000 Rockville, MD.

Implementation of Quality-by-Design: ONDQA Initiatives Advisory Committee for Pharmaceutical Science October 5, 2006 Chi-wan Chen, Ph.D. Deputy Director.

Experiences and Lessons Learned from Essential Use Nominations in Developed Countries: Industry Perspectives Peter Blenkinsop on behalf of the International.

What Do Toxicologists Do?

Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.

Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.

FDA Nasal BA/BE Guidance Overview

Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

ITFG/IPAC Collaboration OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working.

IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.

Scientific Data for Evidence- Based Drug Regulation Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration.

ITFG/IPAC Collaboration CMC Specifications Technical Team ITFG/IPAC TECHNICAL TEAM: CMC SPECIFICATIONS Presented by: Bo Olsson, PhD 26 April 2000 Rockville,

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

1 The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction.

IPAC-RS GMP Guideline for OINDP Component Suppliers: Development, Application, and Use Barbara Falco (KOS), Chair of IPAC-RS Supplier Quality Control Working.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

1 The June 1999 Draft BA/BE Guidance for Nasal Aerosols and Nasal Sprays: History, Recommendations and Local Delivery Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA.

Secretary’s Advisory Committee on Human Subjects Protections (SACHRP) Summary of Responses on: Advanced Notice of Proposed Rulemaking (ANPRM) on Holding.

1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.

The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.

NDAC December 14, Nonprescription Drugs Advisory Committee Meeting Silver Spring, Maryland December 14, 2007 Mary S. Robinson, MS Division of Nonprescription.

Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update Moheb M. Nasr, Ph.D. Office of New Quality Assessment (ONDQA,

Office of Pharmaceutical Sciences

Bioequivalence Studies and Other Recommendations for Orally Inhaled and Nasal Drug Products: Work of the ITFG/IPAC-RS Collaboration Presented by Cynthia.

Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.

1 ORALLY INHALED AND NASAL DRUG PRODUCTS FOR LOCAL ACTION Current FDA BA/BE Background and Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA OINDP Subcommittee.

The Pharmaceutical Industry and International Clinical Research: One Company’s Approach Michael Clayman, M.D. Vice President, Lilly Research Laboratories.

Welcome and Introduction Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory and Ophthalmologic Drug Products ODEV/CDER.

Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview

Guidance Update: Average, Population, and Individual Approaches to Establishing Bioequivalence Mei-Ling Chen, Ph.D. Associate Director Office of Pharmaceutical.

1 Subcommittee Report: Orally Inhaled and Nasal Drug Products (OINDP) Wallace P. Adams, Ph.D. OPS/CDER/FDA Advisory Committee for Pharmaceutical Science.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

1 Dose Content Uniformity for Aerosol Products Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 13 March 2003 Rockville, MD.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

1 PTIT for DCU of OINDP: Approaches to Resolution of Identified Issues Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 21.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

ITFG/IPAC Collaboration BA/BE Technical Team ITFG/IPAC TECHNICAL TEAM: BA/BE IN VITRO AND IN VIVO TESTS Presented by: Stephen Farr, PhD 26 April 2000 Rockville,

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team ITFG/IPAC TECHNICAL TEAM: SUPPLIER QUALITY CONTROL (QUALIFICATION) Presented by: Gordon.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

1 Neil Flanzraich Vice Chairman and President Pulmonary-Allergy Drugs Advisory Committee Meeting June 10, 2004.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Peter Karlton 1 Regulatory Challenges A Diversity of Considerations Ethical Cultural Regulatory standards Strained resources Competing priorities Training.

12/4/031 Drug Safety and Risk Management Advisory Committee Advancing the Science of Proprietary Drug Name Review Paul J. Seligman, MD.

Orally Inhaled and Nasal Drug Products (OINDP) Subcommittee Report to the Advisory Committee for Pharmaceutical Sciences Rockville, Maryland November 15,

ITFG/IPAC Collaboration CMC Leachables and Extractables Technical Team ITFG/IPAC TECHNICAL TEAM: CMC LEACHABLES AND EXTRACTABLES Presented by: Kaushik.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Parametric Tolerance Interval (PTI) Test for Delivered Dose Uniformity (DDU) for Orally Inhaled and Nasal Drug Products (OINDP) Michael Golden On behalf.

HIMSS Standards Activities

Thomas T. Mercer Joint Prize

GLOBAL INHALER MARKET RESEARCH AND FORECAST Orion Market Research.

Suzanne M. Sensabaugh, MS, MBA

Beyond Science and Decisions: Problem Formulation to Dose Response

Presentation transcript:

ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD

ITFG/IPAC Collaboration Introduction ITFG The Inhalation Technology Focus Group (ITFG) of the American Association of Pharmaceutical Scientists is comprised of pharmaceutical scientists who seek to foster and advance the art and science of pharmaceutical aerosol products, aerosol technology and related processes

ITFG/IPAC Collaboration Introduction IPAC The International Pharmaceutical Aerosol Consortium (IPAC) is an association of companies that develop and manufacture orally inhaled and nasal products for local and systemic treatment of asthma, chronic obstructive pulmonary disease (COPD), rhinitis, and migraine, as well as new products for non-respiratory disease indications such as diabetes

ITFG/IPAC Collaboration Introduction DRAFT FDA GUIDANCES FOR OINDP Draft Guidances for Industry: 1)Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation; 2)Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation; and 3)Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action

ITFG/IPAC Collaboration Introduction PERSPECTIVE OF ITFG and IPAC ITFG and IPAC: share FDA’s goal of assuring the highest levels of safety, efficacy and quality of OINDP and making these products available to patients expeditiously recognize the value of having OINDP guidance documents to facilitate the development and approval of new medications, but believe that differing views surround CMC and BA/BE issues believe that these differences need to be resolved through the process of a science-based dialogue so that the OINDP Guidances can bring maximum value to regulators and industry, and most of all, to patients and physicians

ITFG/IPAC Collaboration Introduction BACKGROUND ON THE COLLABORATION June 1999: AAPS/FDA/USP Workshop on OINDP Regulatory Issues IPAC presents a Statement proposing a consensus building process The ITFG endorses IPAC’s Statement The Agency agrees to consider IPAC’s proposal further September 1999: ITFG and IPAC agree to undertake a data-driven collaborative effort The objectives of the Collaboration are to: utilize the combined expertise and experience of scientists from IPAC Member Companies and AAPS Inhalation Technology Focus Group expand the knowledge base of the relevant science of OINDP facilitate common Understanding on CMC and BA/BE issues in order to provide the Agency and the Subcommittee with timely technical reports and recommendations for consideration during the Subcommittee’s deliberations

ITFG/IPAC Collaboration Introduction FRAMEWORK OF THE COLLABORATION The ITFG/IPAC Collaboration is overseen by the ITFG/IPAC Steering Committee The Collaboration includes the following five Technical Teams: BA/BE In Vitro and In Vivo Tests Technical Team CMC Specifications Technical Team CMC Tests and Methods Technical Team CMC Supplier Quality Control Technical Team CMC Leachables and Extractables Technical Team Technical Teams are in the process of collecting data and scientific information to investigate selected BA/BE and CMC issues in the draft Guidances Steering Committee provides guidance to Technical Teams and reviews the findings

ITFG/IPAC Collaboration Introduction FRAMEWORK OF ITFG/IPAC COLLABORATION TECHNICAL TEAMS (Representatives of ITFG and IPAC) BA/BE IN VITRO AND IN VIVO TESTS CMC SPECIFICATIONS DOSE CONTENT UNIFORMITY PARTICLE SIZE DISTRIBUTION CMC SUPPLIER QUALITY CONTROL CMC LEACHABLES AND EXTRACTBLES CMC TESTS AND METHODS STEERING COMMITTEE (Representatives of ITFG and IPAC)

ITFG/IPAC Collaboration Introduction PARTICIPATION IN THE COLLABORATION 3M Pharmaceuticals Agouron Aradigm AstraZeneca Aventis Bespak BI Roxane Boehringer Ingelheim Dura Pharmaceuticals Eli Lilly Glaxo Wellcome Inhale Therapeutic Systems Inspire Pharmaceuticals IVAX Kos Pharmaceuticals Lovelace Respiratory Institute Magellan Laboratories Pfeiffer Presspart Primedica Schering-Plough Trudell Medical University of Rhode Island Valois Approximately 85 individuals and more than 20 companies are participating in the ITFG/IPAC Collaboration. Participants are from the following companies/institutions:

ITFG/IPAC Collaboration Introduction WORK OF TECHNICAL TEAMS In separate presentations today, leaders of the ITFG/IPAC Technical Teams will: provide an overview of the work of each Technical Team and describe the Collaboration’s commitment to contribute constructively to the deliberations of the OINDP Subcommittee and the Agency’s development of the OINDP Guidance documents

ITFG/IPAC Collaboration Introduction RECOGNITION OF AGENCY’S COMMITMENT TO IMPROVING QUALITY OF OINDP ITFG and IPAC recognize and appreciate the significant effort made by the Agency to issue the draft product quality OINDP Guidances ITFG and IPAC strongly support the creation of the OINDP Subcommittee and are pleased to be able to participate in today’s meeting We thank the Subcommittee and the Agency for considering our comments and proposals